In this special edition of PharmaVentures Insights, Dr Fintan Walton, Founder & CEO, leads a panel discussion to address whether a duel strategy of approaching both a pharmaceutical company for partnering, and a VC for funding at the same time, is the best way forward for an emerging biotech.

Panelists include Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation at Novo Nordisk, Jeanne Bolger, Vice President, Venture Investments at J&J Innovation, Bart Dzikowski, Managing Director, Head of Transactions & Legal at Novartis Venture Fund, Tim Luker, Senior Director, External Innovation, Global External R&D at Eli Lilly and Kevin Johnson, Co-Founder at Medicxi.